Pailin Biology (000403.SZ): Intravenous human immunoglobulin (pH4) obtains clinical trial batch of drugs.

Wisdom Finance and Economics APP News, Palatin Biotech (000403.SZ) announced that recently, its wholly-owned subsidiary, Guangdong Shuanglin Biopharmaceutical Co., Ltd. (hereinafter referred to as "Guangdong Shuanglin"), has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (Notice No.: 2025LP03518), which allows Guangdong Shuanglin to conduct clinical trials after changing the production process of intravenous human immunoglobulin (pH4).